Alkermes account plan
Developing medicines for neurological disorders
At a glance
Alkermes is an Ireland-headquartered neuroscience biopharma selling psychiatry, addiction and sleep medicines in the U.S., with about 2,050 employees.
Alkermes plc is a neuroscience biopharmaceutical company headquartered in Dublin, Ireland, with a corporate office and R&D center in Massachusetts and a manufacturing plant in Wilmington, Ohio. It sells VIVITROL (addiction), ARISTADA and LYBALVI (schizophrenia and bipolar I disorder) and, since the Avadel acquisition of February 12, 2026, LUMRYZ (narcolepsy) in the U.S., and earns manufacturing and royalty revenues on Janssen's long-acting INVEGA products, RISPERDAL CONSTA and Biogen's VUMERITY. FY2025 total revenues were $1,475,899 thousand and net income from continuing operations $241.7 million (vs $372.1 million in 2024). It had approximately 2,050 full-time employees as of February 20, 2026, about 1,950 of them in the U.S. The company is managed as one segment; Blair Jackson became Chief Executive Officer in 2026, succeeding Richard Pops.
Business units
Addiction: VIVITROL
about 32% of FY2025 revenues ($467.9 million)Once-monthly naltrexone injection for alcohol dependence and prevention of relapse to opioid dependence, made in Wilmington, Ohio, and promoted by a sales force of approximately 105 people. Net sales rose $10.6 million in FY2025; Q3 2026 sales were $127.6 million and 2026 guidance is $460-480 million. Generic versions are expected to enter the market in 2027.
Psychiatry: ARISTADA / ARISTADA INITIO
about 25% of FY2025 revenues ($370.0 million)Long-acting injectable aripiprazole lauroxil for schizophrenia, with one-month, six-week and two-month dosing. Patents run to 2039; Q3 2026 sales were $103.9 million with units up 9%, and 2026 guidance is $365-385 million.
Psychiatry: LYBALVI
about 23% of FY2025 revenues ($346.7 million)Once-daily oral olanzapine plus samidorphan for adults with schizophrenia or bipolar I disorder, and the fastest grower in FY2025 (units up 19%). It shares a psychiatry sales force of approximately 435 people with ARISTADA; payer access reached about 80% of covered lives in 2026 and 2026 guidance is $380-400 million.
Sleep: LUMRYZ
Once-at-bedtime extended-release sodium oxybate for cataplexy or excessive daytime sleepiness in narcolepsy, acquired with Avadel on February 12, 2026 together with a sales force of approximately 60 people. It recorded $89.9 million in Q3 2026 and $226.0 million since closing, with about 4,100 patients on therapy; Alkermes expects to record $315-335 million in 2026.
Manufacturing and royalty revenues
about 20% of FY2025 revenues ($291.3 million)Royalties and manufacturing revenue from Janssen's long-acting INVEGA products, RISPERDAL CONSTA and Biogen's VUMERITY. Revenues fell from $474.1 million in 2024 after the U.S. INVEGA SUSTENNA royalty expired in August 2024 and FAMPYRA manufacturing ended; Q3 2026 revenues were $62.9 million.
Strategic priorities
- Execution under a new CEO
- Blair Jackson's first quarterly call (November 3, 2026) named three priorities: advancing the pipeline with rigor and urgency, driving strong commercial and financial performance, and allocating capital thoughtfully.
- Orexin 2 receptor agonist pipeline
- Alixorexton is in phase 3 Brilliance studies in NT1 and NT2, with topline results beginning in mid-2027, and in phase 2 Vibrance-3 in idiopathic hypersomnia. About six medium- or late-stage programs report over the next 12 months, per the CEO in November 2026.
- Leadership in sleep medicine
- LUMRYZ and its narcolepsy commercial organisation are meant to support the potential launch of alixorexton. Positive phase 3 REVITALYZ data in idiopathic hypersomnia (May 2026) support an sNDA with a potential launch in March 2028.
- Expansion beyond sleep
- ALKS 7290 showed positive phase 1 ADHD data (September 21, 2026) and is in phase 2 in ADHD (data in the second half of 2027) and a 150-patient phase 2 in MDD. ALKS 4510 is planned for a phase 2 in fatigue associated with MS or Parkinson's disease.
- Grow the proprietary portfolio
- Management expects proprietary product net sales of nearly $1.6 billion in 2026, with LYBALVI prescription volume growing nearly 20% in 2027 after its access expansion.
Latest results
In Q3 2026 (quarter to September 30, 2026), total revenues were $480,132 thousand against $394,185 thousand a year earlier, and proprietary net sales rose 31% to $417.3 million, primarily due to the addition of LUMRYZ. Net income fell to $16.3 million from $82.8 million, and the first nine months show a net loss of $49.7 million, driven by Avadel deal costs, the $121.6 million LUMRYZ inventory step-up, intangible amortization and $27.6 million of quarterly interest expense. Adjusted EBITDA was $120.1 million and cash and investments $787.6 million. Management reiterated 2026 guidance across all line items, with Q4 proprietary sales of $400-420 million; for 2027 it expects lower cost of goods, broadly similar SG&A and higher R&D, with full guidance in February.
Investments and deals
- Avadel acquisition
- Completed February 12, 2026 for $21.00 per Avadel share in cash plus a CVR of up to $1.50; cash consideration paid at closing was $2,199.2 million. It added LUMRYZ and a narcolepsy sales force of approximately 60 people.
- Acquisition financing
- A $1.525 billion senior secured term loan A and B package replaced the bridge facility; after the August 12, 2026 amendment the TLA stands at up to $745.3 million and the TLB at up to $773.1 million, both due 2031.
- Rising R&D spend
- R&D rose to $324.0 million in FY2025 (from $245.3 million) and to $121.1 million in Q3 2026 (vs $81.7 million), with R&D headcount up 16% in the quarter; R&D expense is expected to increase again in 2027.
- Capital expenditure
- Capex is guided at approximately $40.0 million to $50.0 million for 2026.
- Share buybacks
- About 1.0 million shares were repurchased in Q1 2026 for $27.7 million; $172.3 million remains authorised under the $400.0 million program.
Challenges and risks
- VIVITROL generic entry
- The company expects generic versions of VIVITROL, its largest product, to enter the market in 2027; Teva and Amneal hold settlement licences.
- Patent litigation and royalty expiries
- Paragraph IV litigation is under way on LYBALVI patents expiring between 2032 and 2041, and the expiry of the U.S. INVEGA SUSTENNA royalty cut long-acting INVEGA revenues to $109.6 million in FY2025 from $236.5 million.
- Orexin competition
- Takeda is launching the first orexin agonist for NT1, and Lilly is investing behind its Centessa acquisition; alixorexton must differentiate on efficacy and dosing flexibility.
- Acquisition debt and integration
- The 10-K flags failure to realise Avadel synergies and new secured debt with covenants as risks; nine-month 2026 operating cash flow fell to $72.9 million from $350.6 million.
- U.S. pricing and controlled-substance rules
- Gross-to-net deductions were 47.7% in Q3 2026 under Medicaid, 340B and Medicare Part D pressure, and LUMRYZ is a DEA-controlled substance under a REMS, made by contract manufacturers.
What leadership says
“We have a clear strategy and a strong foundation. Our focus now is on execution.”
“the next year will be a pivotal and data-rich period for Alkermes, with six important studies expected to read out across our orexin portfolio.”
“We have generated over $1.8 billion of revenue this year. We are highly profitable.”
“We are a profitable neuroscience company with a late-stage candidate and leadership in an exciting new therapeutic category.”
Where a supplier can help
- Clinical trial operations
- Six orexin readouts in the next year, three phase 3 Brilliance studies and new phase 2 studies in ADHD, MDD and fatigue create demand for site management, patient recruitment and trial data services.
- Sleep-medicine commercial launch support
- The goal of leadership in sleep medicine, the LUMRYZ IH sNDA and a potential alixorexton launch call for HCP targeting, market access and field-force tools for the narcolepsy organisation.
- Integration and finance tooling
- Integrating Avadel, servicing term loans with covenants and an 18% rise in sales and marketing headcount point to needs in finance, HR and CRM integration.
- Gross-to-net and market access analytics
- Gross-to-net deductions near 47.7% and Medicare Part D pressure on LYBALVI make rebate management, contracting and pricing analytics a direct lever on net sales.
- Manufacturing quality and supply
- Out-of-specification batch costs on ARISTADA and VIVITROL, reliance on contract manufacturers for LUMRYZ and DEA quotas open room for quality, supply-chain and compliance suppliers.
Tamtam's reading of the priorities and challenges above, not the company's own words.
Selling to companies like Alkermes?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companiesKey documents
Read in full by Tamtam; each summary links to the document itself.
- Alkermes plc Annual Report on Form 10-K for the year ended December 31, 2025
- Alkermes plc is an Ireland-headquartered neuroscience biopharma (corporate office and R&D center in Massachusetts, manufacturing plant in Wilmington, Ohio) selling ARISTADA/ARISTADA INITIO, LYBALVI and VIVITROL in the U.S., and earning royalties/manufacturing revenue on Janssen's long-acting INVEGA products, RISPERDAL CONSTA and Biogen's VUMERITY; it is managed as one segment.
- FY2025 total revenues were $1,475,899 thousand; product sales, net rose to $1,184.6 million (from $1,083.5 million) while manufacturing and royalty revenues fell to $291.3 million (from $474.1 million) after the U.S. INVEGA SUSTENNA royalty expired in August 2024.
- By product: VIVITROL $467.9 million, ARISTADA family $370.0 million, LYBALVI $346.7 million (+$66.7 million, units up 19%); net income from continuing operations $241.7 million vs $372.1 million in 2024.
- On February 12, 2026 it closed the Avadel Acquisition ($21.00 per share in cash plus a $1.50 CVR), adding LUMRYZ (once-at-bedtime sodium oxybate for narcolepsy, orphan exclusivity to 2030/2031) and a narcolepsy sales force of approximately 60 people; funded by a $1.525 billion term loan A/B package plus cash.
- R&D rose to $324.0 million (alixorexton external spend $95.8 million); alixorexton (orexin 2 receptor agonist, FDA Breakthrough Therapy in NT1, December 2025) was to start phase 3 in narcolepsy in Q1 2026; ALKS 4510 and ALKS 7290 entered the clinic in 2025.
- Approximately 2,050 full-time employees as of February 20, 2026 (about 1,950 in the U.S., 100 in Ireland); sales forces of about 435 (ARISTADA/LYBALVI) and 105 (VIVITROL).
- Key risks: generic VIVITROL expected in 2027, Paragraph IV litigation on LYBALVI patents, Avadel integration and new secured debt, LUMRYZ REMS and DEA controlled-substance rules, Medicaid/340B pricing pressure.
- Capex guided at $40.0 million to $50.0 million for 2026; operating cash flow was $520.8 million in 2025.
- Alkermes plc Quarterly Report on Form 10-Q for the quarter ended September 30, 2026
- Q3 2026 (quarter to September 30, 2026; 10-Q filed November 3, 2026): total revenues $480,132 thousand vs $394,185 thousand a year earlier; nine-month revenues $1,369,052 thousand vs $1,091,352 thousand.
- Proprietary product sales, net $417.3 million (vs $317.4 million): VIVITROL $127.6 million, ARISTADA family $103.9 million, LYBALVI $95.9 million, LUMRYZ $89.9 million (nine months: $226.0 million).
- Manufacturing and royalty revenues fell to $62.9 million (from $76.8 million): VUMERITY $29.5 million, long-acting INVEGA $26.4 million.
- Net income $16.3 million vs $82.8 million; nine-month net loss of $49.7 million, driven by Avadel deal costs, the $121.6 million LUMRYZ inventory step-up, $19.7 million quarterly intangible amortization and $27.6 million quarterly interest expense.
- R&D rose to $121.1 million (alixorexton $39.1 million, other orexin programs $14.9 million); SG&A $208.5 million with an 18% rise in sales and marketing headcount from the LUMRYZ organisation.
- Pipeline: alixorexton in phase 3 Brilliance Studies (NT1, NT2) and phase 2 Vibrance-3 (IH); LUMRYZ positive phase 3 REVITALYZ in IH (May 2026); ALKS 7290 positive phase 1 ADHD data (September 21, 2026), now in phase 2 in ADHD and MDD.
- Balance sheet: cash and investments $787.6 million; term loans of up to $745.3 million (TLA) and $773.1 million (TLB) after the August 2026 amendment; nine-month operating cash flow $72.9 million.
- A 6% list price increase took effect January 1, 2026 for ARISTADA, LYBALVI and VIVITROL; ARISTADA units up 9% and LYBALVI units up 16% in the quarter.
- Alkermes Q3 2026 earnings call transcript
- First quarterly call of Blair Jackson as CEO (November 3, 2026): priorities are "execution", advancing the pipeline "with rigor and urgency", strong commercial performance and disciplined capital allocation.
- Q3 2026 proprietary net sales up 31% to $417.3 million; total revenues $480.1 million; adjusted EBITDA $120.1 million; GAAP net income $16.3 million; cash and investments about $787.6 million.
- 2026 guidance reiterated: VIVITROL $460-480 million, ARISTADA $365-385 million, LYBALVI $380-400 million, LUMRYZ $315-335 million recorded by Alkermes; Q4 proprietary sales $400-420 million; proprietary portfolio "nearly $1.6 billion" in 2026.
- LUMRYZ reached about 4,100 patients on therapy; REVITALYZ in IH supports an sNDA with a potential launch in March 2028.
- LYBALVI payer access expanded to about 80% of covered lives; gross-to-net about 42% in Q3, about 45% expected in 2027 with prescription volume growing nearly 20%.
- Orexin pipeline: six studies read out over the next year, including Vibrance-3 (about 130 participants, IH), three phase 3 Brilliance studies from mid-2027, ALKS 7290 phase 2 in ADHD (second half 2027) and a new 150-patient phase 2 in MDD, ALKS 4510 phase 2 in MS/Parkinson's fatigue.
- 2027: lower cost of goods as the LUMRYZ inventory step-up runs off, broadly similar SG&A, higher R&D; full guidance in February.
- On Takeda's NT1 orexin launch, management expects only a marginal early impact on oxybates and sees the two mechanisms as complementary.
- Alkermes CEO Blair Jackson at the Stifel 2026 Healthcare Conference
- Blair Jackson, CEO, at the Stifel 2026 Healthcare Conference (November 10, 2026): 2026 was "a whirlwind of a year": Avadel acquired, positive LUMRYZ phase 3 in IH, orexin program in phase 3, first ADHD data for ALKS 7290.
- About six medium- or late-stage programs report over the next 12 months (narcolepsy, ADHD, fatigue) plus the LUMRYZ IH filing; the commercial business generated "over $1.8 billion of revenue this year" and is "highly profitable".
- IH readout: about 25% of IH patients are long sleepers; NT2 data are the benchmark (about 70% normalised on once-daily dosing); a 4-point ESS change is clinically meaningful; a phase 3 would follow even without p<0.05 if the signal supports it.
- Phase 3 in NT1/NT2 started mid-summer and should take about a year to enrol; European sites are enrolling well.
- Orexin competition (Takeda, Lilly via Centessa): efficacy and dosing flexibility decide hypersomnolence; first-mover advantage matters more in big indications such as depression. Expects Takeda's NT1 launch to go "quite well", with about 100,000 patients who tried oxybates without success.
- ADHD: phase 1b was not placebo-controlled ("you need to be cautious"); the preferred profile is stimulant-like efficacy with a clean safety profile; placebo-controlled phase 2 data in the second half of next year.
- Fatigue (MS, Parkinson's) and MDD (about 50% with excessive sleepiness) are the next frontiers; LUMRYZ is not substitutable by XYREM generics.
- He argues investors underrate a "long tail" for VIVITROL (hard to copy, Teva manufacturing issues) and LYBALVI patents into "the late 2030s".
- Alkermes at the 44th Annual J.P. Morgan Healthcare Conference
- Richard Pops, then CEO, at the 44th J.P. Morgan Healthcare Conference (January 13, 2026): Alkermes is "a profitable neuroscience company with a late-stage candidate and leadership in an exciting new therapeutic category".
- The commercial business generated "more than $1.4 billion in total revenues" in 2025, with over $1.3 billion of net sales from VIVITROL, LYBALVI and ARISTADA.
- He sizes narcolepsy and IH for orexin agonists at "in excess of $10 billion a year": about 200,000 U.S. narcolepsy patients (half diagnosed, 80,000 treated, about 80% with residual symptoms) and about 40,000 diagnosed IH patients; oxybates reached $1.8 billion of sales in 2024.
- ALKS 2680 (alixorexton) Vibrance-1 and -2 (over 90 patients each, more than 40 sites) were positive; Breakthrough Therapy in NT1; phase 3 "Brilliance" of 12-week studies with once-daily and split dosing to start after the end-of-phase-2 meeting with FDA.
- Next orexins: ALKS 7290 in ADHD (15.5 million U.S. adults diagnosed) and ALKS 4510 in fatigue of MS and Parkinson's (about one million patients each).
- The Avadel deal adds LUMRYZ ($390 million cumulative sales, about $250 million over the trailing 12 months), is expected to be accretive in 2026, and is financed with cash and new debt, with no Alkermes stock.
- Differentiation versus Takeda: NT1 and NT2 in one filing, a range of once-daily doses and a split-dose option; the moat is "Data".
- VIVITROL has "more error bars" as a Teva generic arrives in 2027; LYBALVI is "growing beautifully" and ARISTADA growth has been re-established.
Questions about Alkermes
What does Alkermes do?
Alkermes develops and sells neuroscience medicines in the U.S.: VIVITROL for addiction, ARISTADA and LYBALVI for schizophrenia and bipolar I disorder, and LUMRYZ for narcolepsy. It also earns royalties and manufacturing revenue on products licensed to Janssen and Biogen.
What is Alkermes' revenue?
FY2025 total revenues were $1,475,899 thousand. In Q3 2026 revenues were $480,132 thousand, and the proprietary portfolio is expected to deliver nearly $1.6 billion of net sales in 2026.
How many employees does Alkermes have?
Approximately 2,050 full-time employees as of February 20, 2026, about 1,950 in the U.S. and about 100 in Ireland.
Who leads Alkermes?
Blair Jackson is Chief Executive Officer; November 3, 2026 was his first quarterly call in the role. Richard Pops was Chairman and Chief Executive Officer at the time of the FY2025 10-K.
What is Alkermes' strategy?
It uses its profitable commercial business to fund orexin 2 receptor agonist research, led by alixorexton in narcolepsy and IH, and aims to become a leader in sleep medicine through LUMRYZ.
Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)